Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141847PMC
http://dx.doi.org/10.1038/s41573-023-00688-4DOI Listing

Publication Analysis

Top Keywords

drug discovery
12
discovery development
12
single-cell rna
8
rna sequencing
8
scrna-seq methods
8
drug
5
scrna-seq
5
applications single-cell
4
sequencing drug
4
development
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!